Background and Summary: Extracorporeal photopheresis (ECP) is a leukapheresis-based procedure used in the therapy of acute and chronic graft-versus-host disease (aGvHD, cGvHD) and other diseases. Based on the substantial efficacy and the excellent safety profile in the absence of immunosuppression ECP has established itself as a major treatment form for steroid-refractory GvHD. Here we review the current literature on ECP as a treatment option for patients with aGvHD as well as cGvHD. Key Messages: ECP is a well-established second-line therapy for cGvHD. Its role in the treatment of aGvHD is less clear but also points towards an effective second-line therapy option. In the future ECP could play a role in the prevention of GvHD. More experimental and randomized controlled trials are needed to define the best patient selection criteria, settings, and therapy regimens for GvHD.

中文翻译：

---

移植物抗宿主病的体外光照

背景和总结：体外光分离术 (ECP) 是一种基于白细胞分离术的程序，用于治疗急性和慢性移植物抗宿主病 (aGvHD、cGvHD) 和其他疾病。基于在没有免疫抑制的情况下的显着疗效和出色的安全性，ECP 已成为类固醇难治性 GvHD 的主要治疗形式。在这里，我们回顾了目前关于 ECP 作为 aGvHD 和 cGvHD 患者治疗选择的文献。关键信息：ECP 是一种成熟的 cGvHD 二线疗法。它在治疗 aGvHD 中的作用尚不清楚，但也指向了一种有效的二线治疗选择。在未来，ECP 可以在预防 GvHD 中发挥作用。需要更多的实验和随机对照试验来确定最佳的患者选择标准、设置、